Loading...
SLGC logo

Standard BioTools Inc.NasdaqGM:SLGC Stock Report

Market Cap US$396.2m
Share Price
n/a
1Y-28.1%
7D-14.3%
1D-4.5%
Portfolio Value
​
View

Standard BioTools Inc.

NasdaqGM:SLGC Stock Report

Market Cap: US$396.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Standard BioTools (SLGC) Stock Overview

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. More details

SLGC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 16.43% per year

Risk Analysis

Volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years


SLGC Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW497,995 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
497,995 investors already sharing narratives
View all narratives

Standard BioTools Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Standard BioTools
Historical stock prices
Current Share PriceUS$2.10
52 Week HighUS$3.79
52 Week LowUS$1.73
Beta1.64
1 Month Change-13.93%
3 Month Change14.13%
1 Year Change-28.08%
3 Year Changen/a
5 Year Changen/a
Change since IPOn/a

Recent News & Updates

Recent updates

Analysis Article • Dec 19

Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

SomaLogic, Inc.'s ( NASDAQ:SLGC ) price-to-sales (or "P/S") ratio of 4.9x may not look like an appealing investment...
Analysis Article • Nov 10

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

SomaLogic, Inc. ( NASDAQ:SLGC ) investors will be delighted, with the company turning in some strong numbers with its...
Analysis Article • Apr 17

SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

SomaLogic, Inc. ( NASDAQ:SLGC ) shareholders are no doubt pleased to see that the share price has bounced 33% in the...
Analysis Article • Apr 02

Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

Today is shaping up negative for SomaLogic, Inc. ( NASDAQ:SLGC ) shareholders, with the analysts delivering a...
Seeking Alpha • Oct 17

SomaLogic appoints former Foundation Medicine chief as executive chair

SomaLogic (NASDAQ:SLGC) said Monday it appointed board member and biotech veteran Troy Cox as executive chair of its board, effective immediately. Chuck Lillis, the company's current chair, continue to serve as a board member. Cox has over 30 years' experience in life sciences and biopharmaceuticals, who'd earlier served as CEO of Foundation Medicine.
Seeking Alpha • Jul 26

SomaLogic acquires Palamedrix to develop next-generation SomaScan Assay

SomaLogic (NASDAQ:SLGC) to acquire Palamedrix, an innovator in DNA nanotechnology, that provides deep scientific and engineering expertise, miniaturization technology and enhanced ease-of-use capabilities that company intends to leverage as it develops the next generation of the SomaScan Assay. Under the terms of the merger agreement, company will pay at closing $35M, comprising $14M in cash and $21M in company stock. Up to an additional $17.5M may be paid in connection with the achievement of certain future revenue-based milestones.  Transaction expected to close in Q3 and is not expected to contribute to revenue. As part of the transaction, company will obtain the intellectual property covering Palamedrix’s core DNA-based technology platform for the integration of molecular biosensors onto chips.
Analysis Article • Jun 06

We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 12

SomaLogic Inc: A Biopharmaceutical Company With An Excellent Upside

SomaLogic offers a pioneering platform for the study and engineering of various proteins, which lends itself to a large number of diseases giving the company a large pipeline. The company’s business approach sees them partner with other companies, selling the rights to utilize their platforms in their research which provides revenue while keeping costs low. The company recently announced that it would lend its services to EPIC for a project that aims to analyze and understand cancer development to predict it in the future.
Analysis Article • Mar 09

Calculating The Intrinsic Value Of SomaLogic, Inc. (NASDAQ:SLGC)

Does the March share price for SomaLogic, Inc. ( NASDAQ:SLGC ) reflect what it's really worth? Today, we will estimate...
Analysis Article • Dec 28

We Think SomaLogic (NASDAQ:SLGC) Can Easily Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Oct 14

SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics

SomaLogic was founded in 2000 by Larry Gold, who earlier founded NeXstar Pharmaceuticals, which was acquired by Gilead (GILD) for $550M. Institutional holders in the company include Ark Investment Management, Perceptive Advisors, Illumina, Softbank, Redmile Group, etc. The SomaScan Discovery Platform can analyze 7000 proteins in just 55 microL of blood sample, over 3.5x than competition. Current customers include Bristol-Myers Squibb (BMY), Novartis, Stanford, University of Cambridge, Henry Ford Health System, Alkahest, Louisiana State University, etc. This could be a 10x potential investment opportunity in a 10+ years time frame even if it occupies just 10% market share in the global proteomics market.

Shareholder Returns

SLGCUS Life SciencesUS Market
7D-14.3%2.1%1.6%
1Y-28.1%16.5%18.6%

Return vs Industry: SLGC underperformed the US Life Sciences industry which returned -2.7% over the past year.

Return vs Market: SLGC underperformed the US Market which returned 21% over the past year.

Price Volatility

Is SLGC's price volatile compared to industry and market?
SLGC volatility
SLGC Average Weekly Movement11.4%
Life Sciences Industry Average Movement8.6%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: SLGC's share price has been volatile over the past 3 months.

Volatility Over Time: SLGC's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1999451Adam Taichwww.somalogic.com

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company’s SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development.

Standard BioTools Inc. Fundamentals Summary

How do Standard BioTools's earnings and revenue compare to its market cap?
SLGC fundamental statistics
Market capUS$396.23m
Earnings (TTM)-US$130.38m
Revenue (TTM)US$81.72m
4.8x
P/S Ratio
-3.0x
P/E Ratio

Is SLGC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SLGC income statement (TTM)
RevenueUS$81.72m
Cost of RevenueUS$97.89m
Gross Profit-US$16.16m
Other ExpensesUS$114.22m
Earnings-US$130.38m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.69
Gross Margin-19.78%
Net Profit Margin-159.54%
Debt/Equity Ratio0%

How did SLGC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/01/09 15:30
End of Day Share Price 2024/01/05 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Standard BioTools Inc. is covered by 3 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kyle MiksonCanaccord Genuity
Brandon CouillardJefferies LLC
Daniel BrennanTD Cowen